Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity Treatment US$ 22.44 Min. order: 1 piece ★★★★★ 4.3 (148 reviews) Sold : Login>>
Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' – NBC Connecticut US$ 20.10 Min. order: 1 piece ★★★★★ 4.8 (134 reviews) Sold : Login>>
Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug US$ 28.98 Min. order: 1 piece ★★★★★ 4.8 (208 reviews) Sold : Login>>
Novo Nordisk's next-gen obesity drug CagriSema trial results disappoint investors US$ 24.50 Min. order: 1 piece ★★★★★ 4.1 (240 reviews) Sold : Login>>
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide US$ 22.60 Min. order: 1 piece ★★★★★ 4.2 (56 reviews) Sold : Login>>
Development of Cagrilintide, a Long-Acting Amylin Analogue US$ 28.84 Min. order: 1 piece ★★★★★ 4.4 (192 reviews) Sold : Login>>